Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD, and was promoted to a Senior Research Fellow in 2020. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of patentable, highly potent and selective, and orally active enzyme inhibitors for targeted cancer therapy.
About me
Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD, and was promoted to a Senior Research Fellow in 2020. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of patentable, highly potent and selective, and orally active enzyme inhibitors for targeted cancer therapy.
About me
Research
Excludes commercial-in-confidence projects.
Discovery of CDK6 inhibitors for treatment of childhood medulloblastoma, Channel 7 Children's Research Foundation of SA, 01/01/2015 - 31/12/2016
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2022 |
1
2
|
| 2021 |
Open access
4
5
|
| 2021 |
Open access
1
|
| 2021 |
4
4
1
|
| 2021 |
1
1
|
| 2021 |
2
2
1
|
| 2020 |
5
6
1
|
| 2020 |
21
20
7
|
| 2019 |
4
3
|
| 2019 |
Open access
5
5
3
|
| 2019 |
Open access
23
21
|
| 2018 |
60
57
8
|
| 2018 |
Open access
15
15
3
|
| 2017 |
Open access
15
14
|
| 2017 |
13
14
2
|
| 2017 |
Open access
25
24
|
| 2017 |
Open access
9
10
2
|
| 2017 |
Open access
45
43
6
|
| 2016 |
18
17
|
| 2016 |
Open access
17
17
|
| 2016 |
12
13
|
| 2016 |
Open access
38
40
5
|
| 2016 |
Open access
10
10
1
|
| 2016 |
Open access
33
33
3
|
| 2015 |
Open access
|
| 2015 |
28
29
4
|
| 2015 |
Open access
14
14
|
| 2015 |
Open access
23
21
6
|
| 2015 |
27
25
4
|
| 2015 |
31
32
3
|
| 2015 |
Open access
79
75
|
| 2014 |
Open access
74
70
10
|
| 2014 |
Open access
57
56
1
|
| 2014 |
Open access
17
16
3
|
| 2014 |
35
32
6
|
| 2013 |
Open access
11
11
11
|
| 2013 |
Open access
17
15
5
|
| 2011 |
33
33
|
| 2010 |
7
7
|
| 2010 |
12
12
|
| 2009 |
|
Research
| Details | Registry | Status |
|---|---|---|
|
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds Wang, Shudong; Zeleke, Solomon Tadesse; Yu, Mingfeng |
WO | Filed |
External engagement & recognition
| Organisation | Country |
|---|---|
| Ain Shams University | EGYPT |
| Cardiff University | UNITED KINGDOM |
| CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
| Griffith University | AUSTRALIA |
| Lebanese American University | LEBANON |
| National Research Centre | EGYPT |
| Newcastle University, United Kingdom | UNITED KINGDOM |
| Open University | UNITED KINGDOM |
| Shanghai Jiao Tong University | CHINA |
| University College London | UNITED KINGDOM |
| University of Adelaide | AUSTRALIA |
| University of Nottingham | UNITED KINGDOM |
| University of Oxford | UNITED KINGDOM |
| University of Potsdam | GERMANY |
| University of South Australia | AUSTRALIA |
| University of Southampton | UNITED KINGDOM |
| University of Sydney | AUSTRALIA |
| Westmead Hospital | AUSTRALIA |
| Yabao Pharmaceutical Group Co., Ltd | CHINA |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
Chartered MemberRoyal Australian Chemical Institute (RACI) |
2018 |
MemberAmerican Association for Cancer Research (AACR) |
2018 |
MemberAmerican Association for the Advancement of Science (AAAS) |
2018 |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Design and synthesis of mnk Inhibitors for targeted cancer therapy | Current |
| Evaluation of the cyclin-dependent kinase CDK inhibitors resistance for cancer treatment | Current |
| Derivatives of 4-(1H-pyrazol-4-yl)pyrimidine CDK2 inhibitors as potential anticancer agents: design, synthesis & evaluation | Completed |
| Discovery of cyclin-dependent kinase 2/5 inhibitors for the potential treatment of cancer | Completed |
| Discovery of novel inhibitors of MAPK-interacting kinases as anti-tumour agents | Completed |
| Novel inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents: design, synthesis and evaluation | Completed |
| Protein kinase inhibitors as potential anti-cancer agents: design, synthesis and evaluation | Completed |
